ATLAS: A phase 3 trial evaluating the efficacy of apalutamide (ARN-509) in patients with high-risk localized or locally advanced prostate cancer receiving primary radiation therapy
Bossi, A., Dearnaley, D., McKenzie, M., Baskin-Bey, E., Tyler, R., Tombal, B., Freedland, S.J., Roach, M., Widmark, A., Dicker, A.P., Wiegel, T., Shore, N., Smith, M., Yu, M., Kheoh, T., Thomas, S., SVolume:
27
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdw372.52
Date:
October, 2016
File:
PDF, 42 KB
english, 2016